NCT04493216 - A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

September 5, 2022

Study Completion Date

May 29, 2023

Conditions

HIV Infections

Interventions

DRUG

GSK3640254

GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.

DRUG

ABC/3TC

ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.

DRUG

FTC/TAF

FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.

DRUG

Dolutegravir

Dolutegravir was available as a 50 mg tablet to be administered via oral route.

DRUG

Placebo

Placebo matching GSK3640254 was administered in the form of tablets via oral route.

Trial Locations (65)

1141

GSK Investigational Site, Buenos Aires

1475

GSK Investigational Site, Vosloorus Ext 2

2113

GSK Investigational Site, Johannesburg

4052

GSK Investigational Site, Wentworth

5400

GSK Investigational Site, San Juan

7925

GSK Investigational Site, Observatory, Cape Town

8091

GSK Investigational Site, Zurich

8916

GSK Investigational Site, Badalona, Barcelona

10149

GSK Investigational Site, Turin

13003

GSK Investigational Site, Marseille

15006

GSK Investigational Site, A Coruña

20127

GSK Investigational Site, Milan

20157

GSK Investigational Site, Milan

25123

GSK Investigational Site, Brescia

28006

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

29600

GSK Investigational Site, Marbella

30003

GSK Investigational Site, Murcia

32803

GSK Investigational Site, Orlando

32806

GSK Investigational Site, Orlando

34982

GSK Investigational Site, Ft. Pierce

41013

GSK Investigational Site, Seville

41014

GSK Investigational Site, Seville

44787

GSK Investigational Site, Bochum

46010

GSK Investigational Site, Valencia

46014

GSK Investigational Site, Valencia

48072

GSK Investigational Site, Berkley

50674

GSK Investigational Site, Cologne

59208

GSK Investigational Site, Tourcoing

68198

GSK Investigational Site, Omaha

75018

GSK Investigational Site, Paris

75246

GSK Investigational Site, Dallas

81675

GSK Investigational Site, Munich

90027

GSK Investigational Site, Los Angeles

190103

GSK Investigational Site, Saint Petersburg

191167

GSK Investigational Site, Saint Petersburg

214006

GSK Investigational Site, Smolensk

420061

GSK Investigational Site, Kazan'

443029

GSK Investigational Site, Samara

39216-4505

GSK Investigational Site, Jackson

45267-0405

GSK Investigational Site, Cincinnati

C1128AAF

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

C1207AAP

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

C1425AWK

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

C1405CKC

GSK Investigational Site, Ciudad Autónoma de Buenos Aires

C1202ABB

GSK Investigational Site, Ciudad de Buenos Aires

C1425AGC

GSK Investigational Site, Buenos Aires

K1H 8L6

GSK Investigational Site, Ottawa

H2L 4E9

GSK Investigational Site, Montreal

H2L 4P9

GSK Investigational Site, Montreal

H4A 3J1

GSK Investigational Site, Montreal

00149

GSK Investigational Site, Rome

2801-951

GSK Investigational Site, Almada

3814-501

GSK Investigational Site, Aveiro

4099-001

GSK Investigational Site, Porto

4200-319

GSK Investigational Site, Porto

03010

GSK Investigational Site, Alicante

08025

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, L'Hospitalet de Llobregat

07010

GSK Investigational Site, Palma de Mallorca